An Open-Label, Long Term Safety and Efficacy Study of Donidalorsen in the Prophylactic Treatment of Hereditary Angioedema (HAE)
An Open-Label, Long Term Safety and Efficacy Study of Donidalorsen in the Prophylactic Treatment of Hereditary Angioedema (HAE) is a PHASE3 clinical asset sponsored by Ionis Pharmaceuticals, Inc. in Hereditary Angioedema. SEO and diligence focus: Donidalorsen, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.
Indication: Hereditary Angioedema
Modality: small molecule
Target: Donidalorsen
Sponsor: Ionis Pharmaceuticals, Inc.
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 22, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: Donidalorsen
View original source fields
Condition raw: Hereditary Angioedema
Condition normalized: Hereditary Angioedema
Modality raw: small molecule
Modality normalized: small molecule
Target raw: Donidalorsen
Target normalized: Donidalorsen